AML
Conference Coverage
Novel trial aims to BEAT AML
SAN DIEGO - A multi-arm clinical trial aims to transform the treatment of acute myeloid leukemia, a deadly blood cancer whose standard of care has...
Conference Coverage
Two mutations may help drive CBF-AML
2016 ASH Annual Meeting SAN DIEGO—Researchers have found evidence to suggest that mutations in the CCND1 and CCND2 genes may contribute to the...
Conference Coverage
Predicting therapy-related myeloid neoplasms
Photo courtesy of MD Anderson Cancer Center SAN DIEGO―Clonal hematopoiesis could be used as a predictive marker to identify cancer patients at...
Conference Coverage
Agent exhibits activity in relapsed/refractory AML
acute myeloid leukemia SAN DIEGO—A next-generation DNA hypomethylating agent has demonstrated clinical activity and an acceptable safety profile...
News
Group estimates global cancer cases, deaths in 2015
receiving chemotherapy Photo by Rhoda Baer Researchers have estimated the global incidence of 32 cancer types and deaths related to these...
Conference Coverage
Combo shows early promise in newly diagnosed AML
© Todd Buchanan 2016 SAN DIEGO—A targeted therapy combined with standard chemotherapy can produce rapid, deep remissions in patients with newly...
Article
VIDEO: Novel, multi-arm trial aims to beat AML
SAN DIEGO - A new multi-arm clinical trial aims to transform the treatment of de novo acute myeloid leukemia, a deadly blood cancer whose standard...
Article
VIDEO: Addition of antibody drug conjugate produces deep AML remissions
After more than four decades of near stagnation in the treatment of patients with acute myeloid leukemia, investigators are beginning to identify...
Conference Coverage
VIDEO: Combination venetoclax-LDAC therapy boosts overall survival in AML
SAN DIEGO – Combination therapy with the BCL-2 inhibitor venetoclax and low-dose cytarabine (LDAC) achieved a 61% overall response rate in older...
Conference Coverage
VIDEO: CPX-351 may allow more high-risk AML patients to have allogeneic transplants
SAN DIEGO – Induction therapy with the investigational drug CPX-351 (Vyxeos), a liposomal formulation of cytarabine and daunorubicin, allowed more...
Conference Coverage
VIDEO: 33A + ‘7 + 3’ equals good remission numbers in untreated AML
SAN DIEGO – An experimental induction regimen combining standard chemotherapy with an antibody drug conjugate induced rapid and deep remissions in...